20/20 Biolabs, Inc. Common Stock (AIDX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol AIDX
- Company 20/20 Biolabs, Inc. Common Stock
- Price $8.41
- Changes Percentage -18.59
- Change -1.92
- Day Low $7.38
- Day High $9.39
- Year High $50
- Year Low $7.38
- Market Cap $41,322,871
- Price Avg 50 EMA (D) $19.32
- Price Avg 200 EMA (D) $19.32
- Exchange NASDAQ
- Volume 125,475
- Average Volume 32,450
- Open $8.65
- Previous Close $10.33
- EPS -0.68
- PE -12.37
- Earnings Announcement 1970-01-01 00:00:00
- Shares Outstanding $4,913,540
Company brief: 20/20 BIOLABS, INC. COMMON STOCK (AIDX )
- Healthcare
- Medical - Devices
- Jiming Zhou
- https://2020biolabs.com
- US
- N/A
- 06-15-2023
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.